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Introduction 
The term sarcopenia, from the Greek meaning loss of flesh, was first suggested in 1989, with more recent 
definitions incorporating the loss of muscle function as well as the loss of muscle mass that occurs with ageing1. 
It is a common and increasingly important condition as populations grow older and it is associated with 
subsequent disability and morbidity. Sarcopenia is also associated with substantial financial cost: the 
healthcare costs of sarcopenia in the USA in 2000 were estimated to be $18.5 billion 2. However perhaps the 
most striking indication of the importance of sarcopenia comes from the evidence linking poor muscle 
function, in particular weak grip strength, to increased all-cause mortality rates in middle-aged and older 
people3. Frailty can be defined as multi-system impairment associated with increased vulnerability to 
stressors4. There is considerable overlap between the two conditions, especially in terms of the physical aspects 
of frailty. The aim of this review is to summarise how research is being translated to the diagnosis and treatment 
of sarcopenia and frailty. 
 
Diagnosis and relevant outcomes 
Diagnostic criteria are clearly essential for the recognition of sarcopenia and frailty in clinical practice. The 
algorithm for sarcopenia published by the European Working Group on Sarcopenia in Older People 
(EWGSOP) in 2010 requires the presence of either low gait speed or low grip strength to then test for low 
muscle mass as shown in Figure 1. There is considerable overlap with the classic frailty phenotype definition 
by Fried et al.5 which also includes low gait speed and low grip strength, as well as weight loss (as a proxy for 
loss of muscle mass), self-reported low physical activity and exhaustion. The presence of three or more of 
these five features indicates frailty. Another approach is to use a frailty index, which is the proportion of a 
number of deficits, such as hearing impairment, that are present in a pre-specified list of 30 or more items 
covering multiple systems4. This approach requires more information to be collected, although it does allow 
the degree of frailty to be assessed. This section will now focus on the objective measures that are common to 
EWGSOP definition of sarcopenia and Fried frailty, namely gait speed, muscle strength and muscle mass. 
How can these characteristics be measured in a clinical setting and what do they tell us about an older person’s 
current and future health?  
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Gait speed 
Older people with slow gait speed have been found to be at an increased risk of subsequent disability, falls, 
cognitive decline, institutionalisation and mortality6. Gait speed is readily assessed in the clinical setting by 
measuring the time taken to walk a set distance, such as 4m, at usual pace. Although there appears to be a 
continuous relationship between gait speed and outcomes such as mortality6, for clinical purposes a range of 
cut-points have been proposed such as 0.8 m/s, as used in the EWGSOP definition for sarcopenia. 
 
Grip strength 
Grip strength has been recommended as the most practical method of measuring muscle strength in the clinical 
setting1 and has been found to correlate physical performance measures in the lower limbs7. The Jamar 
dynamometer is the most commonly described device8. In a systematic review, seven out of 10 studies of older 
people found that weak grip predicted either incident disability or worsening of existing disability9. Weaker 
grip strength has also been associated with increased length of hospital stay10. There is strong evidence linking 
grip strength with mortality rates, with a meta-analysis of 14 studies showing a graded relationship between 
weaker grip and increased risk of death3; the hazard ratio comparing the lowest to the highest quarters of grip 
strength was 1.67 (95% CI: 1.45, 1.93). Whereas associations between measures of physical performance and 
mortality have been assessed mainly in older populations, four of the studies included in the grip strength meta-
analysis had an average age at baseline of below 60 years, and the findings here were similar. Normative data 
are available for grip11,12 and cut-points have been proposed including those from the FNIH Sarcopenia Project 
which found that cut-points of 26kg in men and 16kg in women best identified individuals with mobility 
disability (assessed using slow gait speed) at ages 65 and older13. 
 
Muscle mass 
Possible techniques for measuring muscle mass in the clinical setting include anthropometry, bioelectrical 
impedance (BIA) and dual energy x-ray absorptiometry (DXA). Anthropometric measures are prone to error 
and are not considered to be suitable for assessing muscle mass in older people1. Bioelectrical impedance 
(BIA), which produces estimates of total fat mass and lean mass, has the advantage over DXA that the 
equipment used is portable. However it has been questioned to what extent BIA provides additional 
information beyond that from anthropometric measurements (weight and height) alone. The third technique, 
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DXA, can accurately estimate the proportion of lean tissue, fat tissue and bone, although access to scanning 
equipment may be a limiting factor. Baumgartner et al.14 proposed an index of relative skeletal muscle mass, 
in the form of appendicular skeletal muscle mass (kg) from DXA divided by height (m) squared. They also 
suggested cut-offs for sarcopenia in the form of two standard deviations below the gender-specific young adult 
mean: 7.26 kg/m2 for men and 5.45 kg/m2 for women. There is evidence that strength may be more predictive 
of the risk of subsequent disability and mortality than muscle mass15. There is also debate around the feasibility 
of measuring muscle mass in the potentially large numbers of older people who may fall below thresholds 
proposed for physical performance and strength16. 
 
Prevalence of sarcopenia and frailty 
Patel et al.17 examined the prevalence of sarcopenia using the EWGSOP definition in the Hertfordshire Cohort 
Study: at mean age 67 years, 4.6% of men and 7.9% of women were found to have sarcopenia. Gale et al.18 
found a similar prevalence of Fried frailty in the English Longitudinal Study of Ageing: 6.5% of those aged 
60-69. Sarcopenia and frailty both increase markedly with age; for example, Gale et al. found that 65% of 
those over 90 met the Fried criteria for frailty. 
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Treatment 
There are a range of potential treatments for sarcopenia and frailty. Most current evidence has used measures 
such as muscle strength and gait speed as outcomes; going forward the optimal measures to use as outcomes 
in trials on sarcopenia and frailty is an important issue. This section describes the established role of exercise 
programmes, along with the potential to modify diet and drug treatments. There is also observational evidence 
that factors across the life course may affect an individual’s likelihood of developing sarcopenia and frailty as 
shown in Figure 2; this exciting potential area for intervention is considered at the end of this section. 
 
Exercise 
Resistance exercise is the most studied form of exercise intervention. The 2009 Cochrane review of the use of 
progressive resistance training to improve physical function19 included studies with an average age of at least 
60, the majority of which were high-intensity programmes performed twice or three times per week in gym or 
clinic-based settings. The outcomes used in different studies varied but there was evidence of a moderate-to-
large beneficial effect on strength in the lower limb, as well as a moderate effect on gait speed. There is also 
evidence that resistance exercise is beneficial for lean mass, with a pooled finding across 49 studies of an 
increase in lean mass of 1.1kg following an average of 20.5 weeks of resistance exercise20. As with physical 
function, the benefits were seen especially in high-intensity programmes. Other types of exercise intervention 
include aerobic exercise, balance and flexibility training and functional training. These have been less studied 
in regard to outcomes related to sarcopenia. 
 
Diet 
Less is known about dietary interventions than the established role of resistance training. There is considerable 
recent literature which suggests that several aspects of diet may be important in the development of 
sarcopenia21. Food intake falls by approximately 25% from 40 to 70 years of age, and particularly if combined 
with a tendency towards a monotonic diet, may lead to inadequate nutrient intake. Three key areas have been 
considered with respect to diet in sarcopenia: protein, vitamin D and antioxidants. 
 
Protein provides the amino acids required for muscle synthesis. There is also evidence that the amino acid 
leucine may activate the signalling pathways leading to protein synthesis. A trial in relatively young (mean 
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age 71) and healthy men failed to show on effect on muscle mass or strength, however, perhaps because the 
group studied tended to have diets already replete in leucine22. There is also a general concern that the muscle 
synthesis in older people following a protein load may be blunted, leading to the suggestion that recommended 
overall protein intakes for older people should be increased to 1.2 – 1.5 g/kg/day23. However a Cochrane review 
found no consistent effect of supplements on functional measures relevant to sarcopenia24. The quantity and 
composition of dietary protein for the prevention and treatment of sarcopenia therefore remains unclear. 
 
The current widespread interest in diseases potentially related to vitamin D deficiency includes sarcopenia and 
frailty.  Evidence supporting a role for vitamin D includes the fact that polymorphisms in vitamin D have been 
linked to muscle strength and frailty has been shown to be associated with vitamin D deficiency. There is 
consensus that low vitamin D levels require replacement23, but as with protein supplementation, intervention 
trials of the effect of vitamin D on strength and physical performance have shown mixed results.  
 
The accumulation of reactive oxygen species (ROS) in older age is recognised to have a role in muscle 
wasting, although the precise forms of ROS responsible and their interactions are not fully understood25. This 
in turn makes it difficult to know which specific antioxidants are likely to be of benefit as supplements and 
there have been few trials. There is evidence from observational studies that those with higher overall 
antioxidant status have better physical function as well as attenuated decline in measures such as walking 
speed26. 
 
In summary, a common finding across the three types of dietary intervention is a mismatch between the 
findings from observational and intervention studies. One possible explanation for this is the tendency for 
intake of dietary components to be highly correlated with one another; hence the association between one 
marker of a healthy diet and physical function may be confounded by other components. Indeed there is 
some evidence linking ‘healthy’ diets, containing wholemeal cereals and greater amounts of fruit and 
vegetables, to greater muscle strength in older people21. An important area for further research is therefore 
the potential of whole-diet interventions, which attempt to change dietary patterns rather than focussing on 
specific nutrients in isolation. 
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Medication 
As yet there is no recommended drug treatment for sarcopenia or frailty. However sarcopenia is now a major 
focus for drug discovery27. This follows in part from the fact that although resistance training has been shown 
to be effective, many older people may be unable or unwilling to exercise at the required intensity. One area 
which has been explored is hormone administration. Growth hormone has been shown to increase muscle mass 
but not clearly alter functional outcomes and is therefore of questionable benefit28. This highlights the 
challenge of choosing outcome measure(s) for trials in sarcopenia. Testosterone supplementation has been 
found to increase both muscle mass and strength in men but has been linked to adverse cardio-vascular events29. 
A current area of interest is in drugs affecting the renin-angiotensin system, and whether these might have 
direct effects on muscle. An observational study initially suggested that ACE (angiotensin converting enzyme) 
inhibitors might be of benefit for physical function, a finding subsequently confirmed in a trial showing 
improved six minute walk time in those given perindopril30. Further trials are ongoing. 
 
A life course approach to sarcopenia and frailty 
A complementary approach to the treatments already described is to consider the aetiological factors for 
sarcopenia and frailty across the life course. This substantially broadens the window for understanding the 
aetiology of these conditions and for developing interventions to prevent or delay their development. The life 
course epidemiology framework views function in old age as the combination of two phases: growth to the 
peak obtained in early adult life and subsequent decline thereafter, as shown in Figure 2.  
 
The association between birth weight and muscle strength was first described in the Hertfordshire Ageing 
Study31. This finding has since been replicated, with a systematic review describing a positive association 
between birth weight and muscle strength in 17 out of 19 studies32. Furthermore longer duration of 
breastfeeding has been linked to higher grip strength in men in the Hertfordshire Cohort Study33. Studies have 
also examined the relationship between lifestyle factors including physical activity in childhood and adulthood 
and muscle strength. For example, in the MRC National Survey of Health and Development, a cumulative 
benefit of increased leisure time physical activity across ages 36, 43, 53 and 60-64 has been found for grip 
strength at age 60-64 years34. Future epidemiological studies will continue to improve our understanding of 
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factors across the life course that may prevent sarcopenia and frailty, including opportunities to examine the 
cellular and molecular mechanisms that underlie such associations35. 
 
Conclusions 
In conclusion, this review has covered recent developments in the diagnosis and treatment of sarcopenia and 
frailty. The development of consensus definitions for sarcopenia has helped to inform clinical assessment of 
patients as well as recruitment into trials. At present, progressive resistance training is the most well studied 
intervention, although access, uptake and response are variable. Research into these conditions is expanding 
exponentially and includes how we might be able to intervene earlier in the life course to prevent their 
occurrence. 
  
Sarcopenia and frailty  Page 9 of 14 
Figures 
 


















Sarcopenia and frailty  Page 10 of 14 


































Sarcopenia and frailty  Page 11 of 14 
Funding statement and competing interests 
R.D. is supported by a Wellcome Trust Fellowship (Grant number WT099055AIA). 
 
No competing interests declared. 
  
Sarcopenia and frailty  Page 12 of 14 
Reference list 
1.  Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, et al. Sarcopenia: European 
consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older 
People. Age Ageing. 2010 Jul;39(4):412–23.  
2.  Janssen I, Shepard DS, Katzmarzyk PT, Roubenoff R. The healthcare costs of sarcopenia in the United 
States. J Am Geriatr Soc. 2004 Jan;52(1):80–5.  
3.  Cooper R, Kuh D, Hardy R, Mortality Review Group. Objectively measured physical capability levels 
and mortality: systematic review and meta-analysis. BMJ. 2010 Sep 9;341:c4467.  
4.  Clegg A, Young J, Iliffe S, Rikkert MO, Rockwood K. Frailty in elderly people. Lancet. 2013 Mar 
2;381(9868):752–62.  
5.  Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, et al. Frailty in Older Adults : 
Evidence for a Phenotype. J Gerontol A Biol Sci Med Sci. 2001;56A(3):M146–56.  
6.  Studenski S, Perera S, Patel K, Rosano C, Faulkner K, Inzitari M, et al. Gait speed and survival in older 
adults. JAMA. 2011 Jan 5;305(1):50–8.  
7.  Visser M, Deeg DJ, Lips P, Harris TB, Bouter LM. Skeletal muscle mass and muscle strength in relation 
to lower-extremity performance in older men and women. J Am Geriatr Soc. 2000 Apr;48(4):381–6.  
8.  Roberts HC, Denison HJ, Martin HJ, Patel HP, Syddall H, Cooper C, et al. A review of the measurement 
of grip strength in clinical and epidemiological studies: towards a standardised approach. Age Ageing. 
2011;40(4):423–9.  
9.  Vermeulen J, Neyens JCL, van Rossum E, Spreeuwenberg MD, de Witte LP. Predicting ADL disability 
in community-dwelling elderly people using physical frailty indicators: a systematic review. BMC 
Geriatr. BioMed Central Ltd; 2011 Jan;11(1):33.  
10.  Kerr A, Syddall HE, Cooper C, Turner GF, Briggs RS, Aihie Sayer A. Does admission grip strength 
predict length of stay in hospitalised older patients? Age Ageing. 2006 Jan;35(1):82–4.  
11.  Bohannon RW, Peolsson A, Massy-Westropp N, Desrosiers J, Bear-Lehman J. Reference values for 
adult grip strength measured with a Jamar dynamometer: a descriptive meta-analysis. Physiother. 2006 
Mar;92(1):11–5.  
12.  Dodds RM, Syddall HE, Cooper R, Benzeval M, Deary IJ, Dennison EM, et al. Grip Strength across 
the Life Course: Normative Data from Twelve British Studies. PLoS One. 2014 Jan;9(12):e113637.  
13.  Alley DE, Shardell MD, Peters KW, McLean RR, Dam T-TL, Kenny AM, et al. Grip strength cutpoints 
for the identification of clinically relevant weakness. J Gerontol A Biol Sci Med Sci. 2014 
May;69(5):559–66.  
14.  Baumgartner RN, Koehler KM, Gallagher D, Romero L, Heymsfield SB, Ross RR, et al. Epidemiology 
of sarcopenia among the elderly in New Mexico. Am J Epidemiol. 1998 Apr 15;147(8):755–63.  
15.  Manini TM, Clark BC. Dynapenia and aging: an update. J Gerontol A Biol Sci Med Sci. 2012 
Jan;67(1):28–40.  
Sarcopenia and frailty  Page 13 of 14 
16.  Keevil VL, Hayat S, Dalzell N, Moore S, Bhaniani A, Luben R, et al. The physical capability of 
community-based men and women from a British cohort: the European Prospective Investigation into 
Cancer (EPIC)-Norfolk study. BMC Geriatr. BMC Geriatrics; 2013 Jan;13(1):93.  
17.  Patel HP, Syddall HE, Jameson K, Robinson S, Denison H, Roberts HC, et al. Prevalence of sarcopenia 
in community-dwelling older people in the UK using the European Working Group on Sarcopenia in 
Older People (EWGSOP) definition: findings from the Hertfordshire Cohort Study (HCS). Age Ageing. 
2013 May;42(3):378–84.  
18.  Gale CR, Cooper C, Sayer A. Prevalence of frailty and disability: findings from the English 
Longitudinal Study of Ageing. Age Ageing. 2014;44(1):162–5.  
19.  Liu C, Latham N. Progressive resistance strength training for improving physical function in older 
adults. Cochrane Database Syst Rev. 2009;(3):CD002759.  
20.  Peterson M, Sen A, Gordon P. Influence of Resistance Exercise on Lean Body Mass in Aging Adults: 
A Meta-Analysis. 2012;43(2):249–58.  
21.  Robinson S, Cooper C, Aihie Sayer A. Nutrition and Sarcopenia: A Review of the Evidence and 
Implications for Preventive Strategies. J Aging Res. 2012;510801.  
22.  Verhoeven S, Vanschoonbeek K, Verdijk LB, Koopman R, Wodzig WKWH, Dendale P, et al. Long-
term leucine supplementation does not increase muscle mass or strength in healthy elderly men. Am J 
Clin Nutr. 2009;89:1468–75.  
23.  Morley J, Argiles J, Evans W, Bhasin S, Cella D, Deutz N, et al. Nutritional recommendations for the 
management of sarcopenia. J Am Med Dir Assoc. 2010;11(6):391–6.  
24.  Milne AC, Potter J, Vivanti A, Avenell A. Protein and energy supplementation in elderly people at risk 
from malnutrition. Cochrane Database Syst Rev. 2009;15(2):CD003288.  
25.  Arthur PG, Grounds MD, Shavlakadze T. Oxidative stress as a therapeutic target during muscle 
wasting: considering the complex interactions. Curr Opin Clin Nutr Metab Care. 2008;11:408–16.  
26.  Kaiser M, Bandinelli S, Lunenfeld B. Frailty and the role of nutrition in older people. A review of the 
current literature. Acta Biomed. 2010;81(S1):37–45.  
27.  Brass EP, Sietsema KE. Considerations in the development of drugs to treat sarcopenia. J Am Geriatr 
Soc. 2011;59(3):530–5.  
28.  Giannoulis MG, Martin FC, Nair KS, Umpleby a M, Sonksen P. Hormone replacement therapy and 
physical function in healthy older men. Time to talk hormones? Endocr Rev. 2012 Jun;33(3):314–77.  
29.  Xu L, Freeman G, Cowling BJ, Schooling CM. Testosterone therapy and cardiovascular events among 
men: a systematic review and meta-analysis of placebo-controlled randomized trials. BMC Med. 2013 
Jan;11:108.  
30.  Sumukadas D, Witham MD, Struthers AD, McMurdo MET. Effect of perindopril on physical function 
in elderly people with functional impairment: a randomized controlled trial. CMAJ. 2007;177(8):867–
74.  
31.  Aihie Sayer A, Cooper C, Evans JR, Rauf A, Wormald RP, Osmond C, et al. Are rates of ageing 
determined in utero? Age Ageing. 1998 Sep;27(5):579–83.  
Sarcopenia and frailty  Page 14 of 14 
32.  Dodds R, Denison HJ, Ntani G, Cooper R, Cooper C, Sayer AA, et al. Birth weight and muscle strength: 
a systematic review and meta-analysis. J Nutr Heal Ageing. 2012;16(7):609–15.  
33.  Robinson SM, Simmonds SJ, Jameson KA, Syddall HE, Dennison EM, Cooper C, et al. Muscle strength 
in older community-dwelling men is related to type of milk feeding in infancy. J Gerontol A Biol Sci 
Med Sci. 2012 Sep;67(9):990–6.  
34.  Dodds R, Kuh D, Aihie Sayer A, Cooper R. Physical activity levels across adult life and grip strength 
in early old age : updating findings from a British birth cohort. Age Ageing. 2013;42(6):794–8.  
35.  Patel HP, Syddall HE, Martin HJ, Stewart CE, Cooper C, Sayer A. Hertfordshire sarcopenia study : 
design and methods. BMC Geriatr. 2010;10(43).  
36.  Aihie Sayer A, Syddall H, Martin H, Patel H, Baylis D, Cooper C. The developmental origins of 
sarcopenia. J Nutr Heal Ageing. Springer; 2008;12(7):427–32.  
 
